Liu Yaping, Wu Qiong, Sun Tiantian, Huang Junxing, Han Gaohua, Han Hexu
Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Jiangsu, China.
Department of Geriatrics, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Jiangsu, China.
Front Oncol. 2022 Oct 6;12:1032579. doi: 10.3389/fonc.2022.1032579. eCollection 2022.
Dynein axonemal assembly factor 5 (DNAAF5) is the transcription factor of regulating the cytoskeleton and hydrodynamic protein complex assembly, however, it was not well elucidated in the malignant progression of hepatocellular carcinoma (HCC).
We investigated the role of DNAAF5 in hepatocellular carcinoma by using multiple groups of clinical tissues combined with data from the TCGA database. Then we overexpressed DNAAF5 in hepatocellular carcinoma tumor tissues, which correlates with poor patient survival outcomes. Furthermore, we constructed stable cell lines of HCC cells to confirm the cancer-promoting effects of DNAAF5 in hepatocellular carcinoma. To explore the mechanisms of DNAAF5, transcriptome sequencing combined with mass spectrometry was also performed, which showed that DNAAF5 affects its downstream signaling pathway by interacting with PFKL and that DNAAF5 regulates PFKL protein stability by recruiting the deubiquitination protein, USP39. To corroborate these findings, the same series of tissue microarrays were used to confirm correlations between DNAAF5 and PFKL expressions. In animal experiments, DNAAF5 also promoted the proliferation of HCC cells.
We found that DNAAF5 expressions were markedly higher in HCC tissues, compared to the adjacent normal tissues. Increased levels of DNAAF5 were associated with significantly worse prognostic outcomes for HCC patients. Cell function experiments showed that HCC cells of overexpressing DNAAF5 exhibited faster proliferation rates, stronger clone formation abilities and higher drug resistance rates. However, tumor cell proliferation rates and colony formation were significantly decreased after DNAAF5 knockout, accompanied by an increase in sensitivity to sorafenib. In addition, the results of our study showed that DNAAF5 accelerates PFKL protein deubiquitination by recruiting USP39 in HCC cells. Furthermore, The overexpression of DNAAF5 could promote HCC cell proliferation and , whereas USP39 knockdown inhibited this effect. Overall, DNAAF5 serves as a scaffold protein to recruit USP39 to form a ternary complex by directly binding the PFKL protein, thereby improving the stability of the latter, which promotes the malignant process of hepatocellular carcinoma.
These findings revealed DNAAF5 was negatively correlated with the prognosis of patients with hepatocellular carcinoma. It underlying mechanism showed that DNAAF5 directly binds PFKL and recruits the deubiquitinated protein (USP39) to improve the stability of the PFKL protein, thus enhancing abnormal glycolysis in HCC cells.
动力蛋白轴丝组装因子5(DNAAF5)是一种调节细胞骨架和流体动力蛋白复合体组装的转录因子,然而,其在肝细胞癌(HCC)恶性进展中的作用尚未得到充分阐明。
我们通过多组临床组织结合TCGA数据库的数据,研究了DNAAF5在肝细胞癌中的作用。然后我们在与患者生存预后不良相关的肝细胞癌肿瘤组织中过表达DNAAF5。此外,我们构建了肝癌细胞稳定细胞系,以证实DNAAF5在肝细胞癌中的促癌作用。为了探究DNAAF5的作用机制,我们还进行了转录组测序和质谱分析,结果表明DNAAF5通过与磷酸果糖激酶-1(PFKL)相互作用影响其下游信号通路,并且DNAAF5通过招募去泛素化蛋白USP39来调节PFKL蛋白的稳定性。为了证实这些发现,我们使用了同一系列的组织芯片来确认DNAAF5与PFKL表达之间的相关性。在动物实验中,DNAAF5也促进了肝癌细胞的增殖。
我们发现,与相邻正常组织相比,DNAAF5在肝癌组织中的表达明显更高。DNAAF5水平的升高与肝癌患者明显更差的预后结果相关。细胞功能实验表明,过表达DNAAF5的肝癌细胞表现出更快的增殖速度、更强的克隆形成能力和更高的耐药率。然而,敲除DNAAF5后,肿瘤细胞增殖率和集落形成明显降低,同时对索拉非尼的敏感性增加。此外,我们的研究结果表明,DNAAF5在肝癌细胞中通过招募USP39加速PFKL蛋白的去泛素化。此外,DNAAF5的过表达可以促进肝癌细胞增殖,而USP39的敲低则抑制了这种作用。总体而言,DNAAF5作为一种支架蛋白,通过直接结合PFKL蛋白招募USP39形成三元复合物,从而提高后者的稳定性,促进肝细胞癌的恶性进程。
这些发现揭示了DNAAF5与肝细胞癌患者的预后呈负相关。其潜在机制表明,DNAAF5直接结合PFKL并招募去泛素化蛋白(USP39)以提高PFKL蛋白的稳定性,从而增强肝癌细胞中的异常糖酵解。